EU Commission Signs Contract With GlaxoSmithKline for Supply of Covid-19 Drug
July 28 2021 - 6:00AM
Dow Jones News
By Cecilia Butini
The European Commission said Wednesday that it has signed a
contract with GlaxoSmithKline PLC for the supply of a monoclonal
antibody that can be used for the treatment of Covid-19.
The Commission said the contract is a procurement framework
contract for sotrovimab, a drug developed by GlaxoSmithKline in
collaboration with VIR Biotechnology Inc.
The treatment is part of a portfolio of five promising
therapeutics which the Commission singled out in June as part of
its Covid-19 therapeutics strategy, and is currently under rolling
review by the European Medicines Agency.
"Sotrovimab can be used for the treatment of coronavirus
patients with mild symptoms who do not require supplemental oxygen,
but who are at high risk for severe COVID-19," according to the
Commission.
According to the agreement with GlaxoSmithKline, member states
can purchase the drug once it has received either emergency
authorization in the state, or a marketing authorization from the
EU Medicines Agency.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 28, 2021 06:49 ET (10:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Jan 2025 to Feb 2025
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Feb 2025
